Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 7/20 | 0.59 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.56 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.50 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.48 |
| ▸ | PTGES2 | Q9H7Z7 | 6/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793726 | 0.94 | PFKFB3 (0.67) | PFKFB3LNPEPPFKFB4PTGES2MMP2 | |
| SCHEMBL793332 | 0.90 | PFKFB3 (0.55) | PFKFB3LNPEPPFKFB4MAP2K4MMP2 | |
| SCHEMBL806077 | 0.88 | PFKFB3 (0.67) | PFKFB3LNPEPPFKFB4MAP2K4MMP2 | |
| SCHEMBL793607 | 0.88 | PFKFB4 (0.64) | PFKFB3LNPEPPFKFB4MAP2K4MMP2 | |
| SCHEMBL792878 | 0.86 | PFKFB3 (0.67) | PFKFB3PFKFB4MAP2K4MMP2MMP9 | |
| SCHEMBL794341 | 0.86 | PFKFB4 (0.54) | PFKFB3PFKFB4MAP2K4MMP2MMP9 | |
| SCHEMBL27943370 | 0.84 | MMP2 (0.59) | PFKFB3PFKFB4MMP2MMP9MMP8 | |
| SCHEMBL793359 | 0.83 | PFKFB3 (0.68) | PFKFB3PFKFB4MAP2K4 | |
| SCHEMBL793857 | 0.83 | PFKFB3 (0.68) | PFKFB3PFKFB4MAP2K4PTGES2 | |
| SCHEMBL794063 | 0.83 | PFKFB4 (0.59) | PFKFB3LNPEPPFKFB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | claimed |
| EP-2616450-A2 | SULFONAMIDE COMPOUNDS | Kancera AB (SE) | 2013-07-24 | — | — | EP | claimed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | claimed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | claimed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| WO-2020080979-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) | 2020-04-23 | — | — | WO | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-9233946-B2 | Sulfonamide compounds | KANCERA AB (SE) | 2016-01-12 | — | — | US | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | KANCERA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035171-A2 | NEW COMPOUNDS | KANCERA AB (SE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | PFKFB3 1/4885LNPEP 3108/4885PFKFB4 2/4885 |
| US-20130172339-A1 | SULFONAMIDE COMPOUNDS | SULT1A1, STS, ARSA | PFKFB3 952/4885LNPEP 3375/4885PFKFB4 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.